Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”
Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.
Ticker Symbol | Company Name | Join Deadline | |
---|---|---|---|
NFE | New Fortress Energy Inc. | November 18, 2024 | Join |
MGX | Metagenomi, Inc. | November 25, 2024 | Join |
BMBL | Bumble Inc. | November 25, 2024 | Join |
UPS | United Parcel Service, Inc. | December 09, 2024 | Join |
EW | Edwards Lifesciences Corporation | December 13, 2024 | Join |
TD | The Toronto-Dominion Bank | December 23, 2024 | Join |